GE HealthCare slip after $945 million deal for Sofie Biosciences

GE HealthCare Technologies

05/10/2026 15:00

** Shares of medical device maker GE HealthCare GEHC.O fall more than 1% to $63.55
** Co says it would buy privately held Sofie Biosciences for $945 million in cash
** Acquisition to give co US rights to FAPI-74, an experimental PET imaging agent in late-stage testing that could be used to detect several types of cancer
** Co already owns rights to the product outside the US
** Says Sofie would continue to manufacture products for existing customers, including other radiopharma companies, after the transaction closes, which is expected in the first half of 2027
** 15 of 21 brokerages rate stock "buy" or above, 6 "hold"; median PT - $85  - data compiled by LSEG
** Including session's moves, stock has fallen 22.5% YTD

 (Reporting by Miraanta Lowrance in Bengaluru)
 ((miraanta.lowrance@thomsonreuters.com))